Integra Biosciences Holding
Integra Biosciences Holding AG, headquartered in Switzerland (CH), is a leading player in the life sciences industry, specialising in innovative liquid handling and automation solutions. Founded in 1965, the company has established a strong presence in Europe, North America, and Asia, catering to laboratories and research institutions worldwide. Integra's core offerings include pipetting systems, automated liquid handling solutions, and consumables, all designed to enhance precision and efficiency in laboratory workflows. Their unique products, such as the VIAFLO and ASSIST series, are renowned for their user-friendly design and reliability, setting them apart in a competitive market. With a commitment to quality and innovation, Integra Biosciences has achieved significant milestones, including numerous patents and awards, solidifying its position as a trusted partner in the scientific community.
DitchCarbon Score
How does Integra Biosciences Holding's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Integra Biosciences Holding's score of 40 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Integra Biosciences Holding's reported carbon emissions
In 2023, Integra Biosciences Holding reported total greenhouse gas emissions of approximately 13,092,000 kg CO2e, comprising 357,000 kg CO2e from Scope 1, 188,000 kg CO2e from Scope 2, and about 13,092,000 kg CO2e from Scope 3 emissions. The company has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions across its value chain by 2050, using 2021 as the base year. Integra has established near-term targets to reduce absolute Scope 1 and 2 emissions by 46.2% by 2031. Additionally, the company plans to increase its sourcing of renewable electricity from 48% in 2021 to 100% by 2030. For Scope 3 emissions, Integra aims to achieve a 55% reduction per million CHF value added by 2031. Long-term goals include a 90% reduction in absolute Scope 1 and 2 emissions and a 97% reduction in Scope 3 emissions per million CHF value added by 2050. These targets align with the Science Based Targets initiative (SBTi) and reflect the company's commitment to addressing climate change effectively.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 208,000 | 000,000 | 000,000 | 000,000 | 000,000 |
| Scope 2 | 498,000 | 000,000 | 000,000 | 0,000,000 | 000,000 |
| Scope 3 | 7,610,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Integra Biosciences Holding is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
